|
|
||||||||||
|
J Am Coll Cardiol, 1991; 17:1277-1282 © 1991 by the American College of Cardiology Foundation |
Department of Medicine, Cook County Hospital, Chicago, Illinois.
Left ventricular hypertrophy has a grave prognosis. Ventricular arrhythmias may account for a large portion of this poor prognosis, but the contribution of coronary artery disease has not been excluded. The occurrence of ventricular arrhythmias was investigated by 24 h ambulatory electrocardiographic (ECG) monitoring in 49 hypertensive patients who had normal findings on coronary arteriography. The presence of left ventricular hypertrophy was assessed by both ECG and echocardiography. The frequency and complexity of ventricular arrhythmias were significantly related to the presence of left ventricular hypertrophy whether it was defined by wall thickness (interventricular septum or posterior wall greater than or equal to 1.2 cm) or by left ventricular mass indexed to height (left ventricular mass/height greater than or equal to 163 g/m in men and greater than or equal to 121 g/m in women). The relation between left ventricular mass or wall thickness to ventricular arrhythmia was graded and continuous; for every 1 mm increase in the thickness of interventricular septum or posterior wall there was an associated two- to threefold increase, respectively, in the occurrence and complexity of ventricular arrhythmias. In conclusion, left ventricular hypertrophy is associated with an increase in the frequency and complexity of ventricular arrhythmias in the absence of coronary artery disease, and the relation is graded and continuous.
This article has been cited by other articles:
![]() |
E. Zakynthinos, Ch. Pierrutsakos, Z. Daniil, and D. Papadogiannis Losartan Controlled Blood Pressure and Reduced Left Ventricular Hypertrophy But Did Not Alter Arrhythmias in Hypertensive Men with Preserved Systolic Function Angiology, July 1, 2005; 56(4): 439 - 449. [Abstract] [PDF] |
||||
![]() |
F. A Babiker, L. J De Windt, M. van Eickels, C. Grohe, R. Meyer, and P. A Doevendans Estrogenic hormone action in the heart: regulatory network and function Cardiovasc Res, February 15, 2002; 53(3): 709 - 719. [Abstract] [Full Text] [PDF] |
||||
![]() |
A Yildirir, M. K Batur, and A Oto Hypertension and arrhythmia: blood pressure control and beyond Europace, January 1, 2002; 4(2): 175 - 182. [Abstract] [PDF] |
||||
![]() |
P. Gaudron, I. Kugler, K. Hu, W. Bauer, C. Eilles, and G. Ertl Time course of cardiac structural, functional and electrical changes in asymptomatic patients after myocardial infarction: their inter-relation and prognostic impact J. Am. Coll. Cardiol., July 1, 2001; 38(1): 33 - 40. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. C. Verduyn, C. Ramakers, G. Snoep, J. D. M. Leunissen, H. J. J. Wellens, and M. A. Vos Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling Am J Physiol Heart Circ Physiol, June 1, 2001; 280(6): H2882 - H2890. [Abstract] [Full Text] [PDF] |
||||
![]() |
G.Y.H Lip, D.C Felmeden, F.L Li-Saw-Hee, and D.G Beevers Hypertensive heart disease. A complex syndrome or a hypertensive 'cardiomyopathy'? Eur. Heart J., October 2, 2000; 21(20): 1653 - 1665. [PDF] |
||||
![]() |
M. A. Quinones, B. H. Greenberg, H. A. Kopelen, C. Koilpillai, M. C. Limacher, D. M. Shindler, B. J. Shelton, D. H. Weiner, and for the SOLVD Investigators Echocardiographic predictors of clinical outcome in patients with left ventricular dysfunction enrolled in the SOLVD registry and trials: significance of left ventricular hypertrophy J. Am. Coll. Cardiol., April 1, 2000; 35(5): 1237 - 1244. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Wolk Arrhythmogenic mechanisms in left ventricular hypertrophy Europace, January 1, 2000; 2(3): 216 - 223. [Abstract] [PDF] |
||||
![]() |
G. Olivetti, E. Cigola, R. Maestri, C. Lagrasta, D. Corradi, and F. Quaini Recent advances in cardiac hypertrophy Cardiovasc Res, January 1, 2000; 45(1): 68 - 75. [Full Text] [PDF] |
||||
![]() |
H. L. Thomson, M. F. O'Brien, A. A. Almeida, P. J. Tesar, M. B. Davison, and D. J. Burstow Haemodynamics and left ventricular mass regression: a comparison of the stentless, stented and mechanical aortic valve replacement Eur. J. Cardiothorac. Surg., May 1, 1999; 13(5): 572 - 575. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Mosterd, R. B. D'Agostino, H. Silbershatz, P. A. Sytkowski, W. B. Kannel, D. E. Grobbee, and D. Levy Trends in the Prevalence of Hypertension, Antihypertensive Therapy, and Left Ventricular Hypertrophy from 1950 to 1989 N. Engl. J. Med., April 22, 1999; 340(16): 1221 - 1227. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. W. Haider, M. G. Larson, E. J. Benjamin, and D. Levy Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death J. Am. Coll. Cardiol., November 1, 1998; 32(5): 1454 - 1459. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. A. Vos, S. H. M. de Groot, S. C. Verduyn, J. van der Zande, H. D. M. Leunissen, J. P. M. Cleutjens, M. van Bilsen, M. J. A. P. Daemen, J. J. Schreuder, M. A. Allessie, et al. Enhanced Susceptibility for Acquired Torsade de Pointes Arrhythmias in the Dog With Chronic, Complete AV Block Is Related to Cardiac Hypertrophy and Electrical Remodeling Circulation, September 15, 1998; 98(11): 1125 - 1135. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Assayag, F. Carre, B. Chevalier, C. Delcayre, P. Mansier, and B. Swynghedauw Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fibrosis Cardiovasc Res, June 1, 1997; 34(3): 439 - 444. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Schillaci, P. Verdecchia, C. Borgioni, A. Ciucci, I. Zampi, M. Battistelli, R. Gattobigio, N. Sacchi, and C. Porcellati Association Between Persistent Pressure Overload and Ventricular Arrhythmias in Essential Hypertension Hypertension, August 1, 1996; 28(2): 284 - 289. [Abstract] [Full Text] |
||||
![]() |
E. D. Frohlich, D. Aristizabal, F. Soria, and F. H. Messerli Investigative Concerns in Demonstrating Reduced Risk from Reversing Left Ventricular Hypertrophy Journal of Cardiovascular Pharmacology and Therapeutics, January 1, 1996; 1(1): 17 - 22. [Abstract] [PDF] |
||||
| HOME | SUBSCRIPTIONS | CURRENT ISSUE | PAST ISSUES | CARDIOSOURCE | SEARCH | HELP | FEEDBACK |